Article Text

Download PDFPDF

BS21 Stabilisation of suppressor of cytokine signalling 3 (SOCS3) to inhibit human saphenous vein smooth muscle cell proliferation and vascular stenosis
Free
  1. Tim Palmer1,
  2. Florah Moshapa2,
  3. Jamie Willliams3,
  4. Kirsten Riches-Suman2,
  5. Jacobo Elies2
  1. 1University of Hull, Hull, UK
  2. 2University of Bradford
  3. 3University of Glasgow

Abstract

Introduction Suppressor of cytokine signalling 3 (SOCS3) limits multiple signalling pathways involved in vascular inflammation and remodelling responsible for neointimal hyperplasia and vein graft failure. However, SOCS3 function is limited by its short biological half-life, suggesting that SOCS3 stabilisation might prove an effective therapeutic strategy. Through identification of SOCS3 ubiquitination sites, we have engineered a novel SOCS3 transgene resistant to proteasomal degradation and assessed its ability to limit signalling pathways and processes responsible for neointimal hyperplasia.

Methods Flag-tagged SOCS3 transiently expressed in HEK293 cells was immunoprecipitated with anti-Flag antibody and fractionated by SDS-PAGE for trypsin digestion. Tryptic peptides were analysed by liquid chromatography and tandem mass spectrometry, and ubiquitination sites identified from di-Gly-modified SOCS3 peptides. Smooth muscle cells (SMCs) and endothelial cells (ECs) from human saphenous vein (HSV) were transduced with recombinant lentiviruses (LVs) with MOIs ranging from 3.6-22.2 tfu/cell. Ubiquitination was assessed by immunoprecipitation of soluble cell lysates and immunoblotting. Half-lives of SOCS3 transgenes were determined by immunoblotting following HSVSMC incubation ± protein synthesis inhibitor emetine. HSVSMC proliferation was assessed by cell counting. Finally, effects of WT and Lys-less SOCS3 gene delivery on cell signalling was determined by assessing phosphorylation of STAT3 (Tyr705) and ERK1/2 (Thr202/Tyr204) by immunoblotting.

Results Analysis of recombinant SOCS3 immunoprecipitated from HEK293 cells revealed that 8 of the 9 Lys residues in human SOCS3 were ubiquitinated. A mutated SOCS3 in which all 9 Lys residues were mutated to Arg was resistant to ubiquitination compared to wild type (WT) SOCS3. LV transduction of WT and Lys-less SOCS3 in HSVSMCs and ECs was highly efficient with >90% of cells expressing SOCS3 transgene after 48 hours. Lys-less SOCS3 was significantly more stable, displaying a biological half-life >4 hours versus <4 hours for WT (n=6, p<0.001). Despite these differences, WT and Lys-less SOCS3 were functionally equivalent in their ability to selectively inhibit STAT3 phosphorylation in response to either sIL-6Rα/IL-6 (74±6% and 80±7% inhibition respectively; n=4, p<0.05 versus controls) or PDGF-BB (67±17% and 72±18% inhibition respectively; n=5) but not ERK1/2 phosphorylation. However, while WT and Lys-less SOCS3 each inhibited cell proliferation in response to sIL-6Rα/IL-6 (83±29% and 89±22% inhibition respectively; n=4, p<0.05 versus controls) only Lys-less SOCS3 significantly inhibited PDGF-BB-stimulated proliferation (67±11% inhibition; n=4, p<0.05 versus controls).

Conclusions These results provide evidence for possible therapeutic targeting of SOCS3 stabilisation to limit HSVSMC dysfunction responsible for vein graft failure.

Conflict of Interest None

  • Vascular re-modelling
  • Inflammation
  • Suppressor of cytokine signalling 3 (SOCS3)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.